Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Lichen Planus

In brief

The purpose is to assess the response of subjects to etanercept (as compared to placebo) in treating the physical signs of mucosal and cutaneous lichen planus. The investigators also wish to assess the effect of etanercept on disease-related itching, pain, and serious adverse events in patients with lichen planus.

Key facts

Study ID

NCT00285779

Run by

Stanford University

People needed

27

Starts

2006-08-01

Expected to finish

2009-11-01

Last updated by the study team

2018-03-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years old.
• Must carry a diagnosis of lichen planus as determined by biopsy
• Patients must have a score of 3 or greater on the physician global assessment (PGA).
• Patient must be considered appropriate for systemic therapy based upon fulfilling one of the following criteria:
• inability to maintain weight due to pain with eating, chewing, or swallowing;
• dyspareunia or dysuria due to genital lesions;
• itch/pain of sufficient severity that activities of daily living are significantly affected
• Must be off systemic lichen planus treatment for 4 weeks prior to starting etanercept
• If using topical corticosteroid to the affected areas, the dose and frequency must be unchanged for 2 weeks prior to beginning the study agent and during the course of the study.
• Must be off topical cyclosporine, tacrolimus, or pimecrolimus for 2 weeks prior to starting the study drug and for the entire duration of the study.
• Must be able and willing to give written informed consent and comply with the requirements of the study protocol and must authorize release and use of protected health information.
• Women of childbearing potential must have a negative pregnancy test at the time of entry into the study and must be practicing successful contraception for at least 3 months prior to the study.
• Subject or designee must have the ability to self-inject investigational product.
• Screening laboratory results are within the following parameters:
• Hemoglobin > 10 g/dL
• White blood cells > 3.5 x 10\^9/L
• Neutrophils > 1.5 x 10\^9/L
• Platelets > 100 x 10\^9/L
• Lymphocytes > 0.5 x 10\^9/L
• Serum creatinine < 1.5 mg/dL
• Hepatitis C serology - nonreactive
• AST and ALT < 2X upper limit of normal (ULN)

You may not qualify if…

• Subject is currently enrolled in another investigational device or drug trial(s), or subject has received investigational agent(s) within 90 days of baseline visit.
• Known HIV-positive status, any other immuno-suppressive disease, or inability to practice safe sex during the length of the study
• Subject has been diagnosed with a malignancy within the past 5 years
• Subject has signs or symptoms of a lymphoproliferative disease.
• Other skin or mucosal disease that might interfere with lichen planus assessments.
• Lichen planus variants including hypertrophic, atrophic, follicular (including lichen planopilaris), and bullous cutaneous forms.
• Patients with lichen sclerosis et atrophicus (LS\&A)
• Clinical history and lesion distribution suspicious for a lichenoid drug eruption
• Severe co-morbidities
• History of tuberculosis (TB) or positive PPD at screening. Known history of active hepatitis B or C, or lupus, SLE, history of multiple sclerosis or prior episode of central nervous system demyelination, transverse myelitis, optic neuritis, epilepsy, psychiatric condition, or other chronic serious medical illnesses.
• Subject has a diagnosis of congestive heart failure (CHF) of any severity
• Use of a live vaccine 90 days prior to, or during this study.
• Previous exposure and/or known sensitivity to etanercept
• Concurrent use, or failure of, any TNF-inhibitor
• Previous exposure to alefacept or efalizumab within 6 weeks of administration of study drug
• Concurrent sulfasalazine therapy
• Prior or concurrent cyclophosphamide therapy
• Active severe infections, or prior infection requiring hospitalization or oral/intravenous antibiotics within 4 weeks before screening visit, or between the screening and baseline visits.
• Active inflammatory bowel disease or peptic ulcer disease
• Drug or alcohol abuse within 12 months of screening visit.
• History of non-compliance with other therapies
• Pregnant or lactating
• Documented presence of any of the following:
• Proteinuria > 1+ by dipstick screening
• 24 Hour protein excretion > 0.5 g

Where it is running

• Stanford University Medical Center — Stanford, California, United States
• Emory University — Atlanta, Georgia, United States
• University of Louisville — Louisville, Kentucky, United States
• Tufts - New England Medical Center — Boston, Massachusetts, United States
• David Fivenson, M.D. Dermatology, PLLC — Ann Arbor, Michigan, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Mount Sinai School of Medicine — New York, New York, United States
• Wake Forest University School of Medicine — Winston-Salem, North Carolina, United States
• University Hospitals of Cleveland — Cleveland, Ohio, United States
• Cleveland Clinic Foundation — Cleveland, Ohio, United States
• Wright State University School of Medicine — Dayton, Ohio, United States
• Oregon Health & Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.